Dr Anthony Fok Neurologist and Neuro-ophthalmologist

Slides:



Advertisements
Similar presentations
The Use of Vitamin D in Clinical Practice
Advertisements

Clinical Trials What Are They and When Are They Right For You? Maura N. Dickler Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering.
A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.
Rare Film Guide Slide Set. Clinical Trial Design for Pirfenidone Study Purpose of Study: To see if the use of pirfenidone decreases the loss of lung function.
How often should they be evaluated and scanned, and how often should they have dermatologic follow-up and EKGs? How should patients responding to BRAF.
 Try to determine causes and risk factors for disease by drawing connections between behaviors or exposures and diseases through observation alone.
Long-term Safety and Effectiveness of Natalizumab STRATA MS Study.
Clinical Trials Importance in future therapies. What are the Requirements to Produce New Drugs? Drug must work significantly better than a control treatment.
Clinical Trials Medical Interventions
Dr. Christina Reith CTSU, University of Oxford ASCEND: A Study of Cardiovascular Events iN Diabetes.
…in an academic collaboration with ISRCTN
Rituximab (RITUXAN) & Multiple Sclerosis
Clinical trial The Way We Make Progress Against Disease Prof. Ashry Gad Mohamed Prof. of Epidemiology College of Medicine & KKUH.
FREEDOMS II TRIAL.
Fingolimod Therapy for Multiple Sclerosis
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 23 Drugs for Multiple Sclerosis.
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-blind, Placebo-controlled Trial Aaron E. Miller,
Arani Nitkunan MA (Cantab), MRCP (UK)(Neurology), PhD February 12th 2015 First Fit Pathway & Multiple Sclerosis.
Multiple Sclerosis (Definition)  “Multiple Sclerosis is a progressive demyelination of neurons in the central nervous system (the Brain and the Spinal.
Drug trials Learning Outcome: DESCRIBE THE USE OF OPEN LABEL, BLIND AND DOUBLE BLIND TESTS IN HUMAN TRIALS (HIGHER) AND THE USE OF PLACEBOS.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Medical Research BADRAG meeting Jan 2013 Dr H Sari-Kouzel.
BAD Biologic Interventions Register (BADBIR ) An update November 2010.
Friends With MS.com Bringing you support and information for Multiple Sclerosis.
Our Experiences With Natural Natural Products As Potential Therapeutic Agents : Towards Safer & Cost Effective Therapy Dr. Mrs.Chanda Kulkarni. MBBS; MD;
British Association of Dermatologists’ Biologic Intervention Register (BADBIR) Update November 2007.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
© 2014 Direct One Communications, Inc. All rights reserved. 1 A New Era of Therapy in Multiple Sclerosis: Balancing the Options and Challenges Ahead Jennifer.
DRUG DEVELOPMENT & REGULATIONS DR ARIF HASHMI. DRUG DEVELOPMENT Discovery and synthesis Preclinical development (chemical testing, biological testing,
Birth defects caused by use of thalidomide Example: Thalidomide From 1956 to 1962, approximately 10,000 children were born with severe malformities,
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Pediatric Endocrinology Use of Biologic and Chemotherapeutic Agents Pediatric Endocrinology Use of Biologic and Chemotherapeutic Agents.
© 2014 Direct One Communications, Inc. All rights reserved. 1 Natalizumab and Dimethyl Fumarate: A Fresh Take on Pivotal Trials and Reports from Ongoing.
Prelude DS ELND005 for Down Syndrome Information for Participants I would like to tell you what this study is about and then you can decide if you would.
Advisory Committee for Peripheral and Central Nervous System Drugs March 7, 2006 Question 1: 1.Has Biogen demonstrated natalizumab’s efficacy on reduced.
What about VIOXX?. Adenomatous Polyp Prevention on Vioxx (APPROVe) Vioxx (rofecoxib) versus Placebo Basic Clinical Trial Objective: Assess whether Vioxx.
Multiple Sclerosis (MS) a serious, chronic and debilitating disease What is MS? A disease of the brain and spinal cord.
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience.
httpwww.youtube.com/watch?v=DhxD6sVQEYc:// The Drug Discovery Process.
Section I General principle of Pharmacology. Where can you get information about general principle of Pharmacology?  Text books:  Katzung, Basic and.
Clinical Trials.
T HE P RESENT AND F UTURE OF MS Scott Belliston, DO Multiple Sclerosis Clinical Fellow.
Zinbryta ™ - daclizumab Manufacturer: Biogen, Inc. FDA Approval Date: May 27, 2016 Jenna W. Bartlett, PharmD Candidate.
Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.
CLINICAL TRIALS.
Is a Clinical Trial Right for Me?
CSNA Clinical Trials NEUROLOGY.
Four Known Types of MS Clinically isolated syndrome (CIS)
Have you been diagnosed with Gorlin Syndrome,
Drug Discovery &Development
Multiple Scleroris Lyle Wiemerslage, PhD.
A 26-y.o. woman with RRMS and eruption of plaques.
CONCLUSION-DISCUSSION
HOPE: Heart Outcomes Prevention Evaluation study
Clinical Trials Medical Interventions
The Role of Statistics in Clinical Trials
Neuro-ophthalmology.
Bozeman Health Clinical Research
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
Treatment of Multiple Sclerosis
Empagliflozin (Jardiance®)
Clinical Trials.
Modifying Disease Course in Alzheimer's Disease
Is a Clinical Trial Right for Me?
Beyond Statin Therapy.
The Chemical Differences Between EPA and DHA.
Figure 1 Effect of DMF therapy on T cell subsets
A Real World Application of the Scientific Method
Multiple Sclerosis is a neurological, immune-mediated disorder
3.4 Building a Better Cancer Treatment
Presentation transcript:

Dr Anthony Fok Neurologist and Neuro-ophthalmologist MS Trials Dr Anthony Fok Neurologist and Neuro-ophthalmologist

Research and Development

IL-37 Study Studying the role of a Interleukin-37 in inflammatory diseases Thought: IL-37 is an inhibitor of inflammation Check IL-37 levels in patients with inflammatory diseases and compare to patients without diseases Need: Consent and blood taken. Future: this may lead to drug development

Vitamin D is thought to play a role in MS PrevANZ Patients with a first clinical attack – Clinically isolated Syndrome Test different doses of Vitamin D3 See whether it can delay or prevent a second episode that would lead to diagnosis of MS Double blind Placebo controlled Treatment for 12 months Collect blood and urine Vitamin D – thought o play a role in MS. Since geographical areas with lower levels of UV radiation – ie have lower vit D synthesis in the skin have higher incidences of MS. Vitamin D3 (cholecalciferol) is produced by the human body in response to sunlight and is also available through dietary sources, such as fish.  Safety Efficacy/safety Efficacy/safety and compare to other drug

Phase IV trial for Tecfidera (dimethyl Fumarate) ESTEEM trial Phase IV trial for Tecfidera (dimethyl Fumarate) Include: all patients starting Tecfidera Followup every 6 months Monitor adverse effects You need to complete questionnaires at each clinic visit – can be done online Phase IV study – done after intervention has been marketed – monitor the effectiveness of the approved intervention and collect info on adverse effects

Multicentre, randomised, double blinded placebo controlled study AFFINITY STUDY Multicentre, randomised, double blinded placebo controlled study Relapsing Remitting MS Add on therapy to other therapies - Interferon (beta1a, beta 1b, beta1a) Dimethyl fumerate Nataluzimab Dx: RRMS EDSS 2-6 MS disease duration <20 years Relapse within 24 months and new lesions on MRI Beta 1a avonex, betaferon – beta 1 b

Ask your friendly neurologist or MS nurse